Description

The Food and Drug Administration (FDA) has granted a compassionate special permit (CSP) for the Covid-19 treatment drug Bexovid, the first generic version of Pfizer’s Paxlovid.

Bexovid may be used for individuals with mild to moderate symptoms of Covid-19 ages 12 years old and above.

It can reduce risks of hospitalization and deaths by 88 to 89 percent when taken within three to five days from the onset of symptoms.